Clinical Trial Update: Expanded Access to Mepsevii

View source ↗

Summary

Expanded access program for Mepsevii (vestronidase alfa) for patients with mucopolysaccharidosis VII is currently available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Vii

Drugs mentioned

• Mepsevii (vestronidase alfa)

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: MPS VII, Mucopolysaccharidosis VII | Status: AVAILABLE